Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers of Glycosaminoglycans (GAG) accumulation in patients with mucopolysaccharidosis type VI-LeukoGAG, Corneal Opacification (COM) and Carotid Intima Media Thickening (CIMT).
Sohn YB, Wang R, Ashworth J, Broqua P, Tallandier M, Abitbol JL, Jozwiak E, Pollard L, Wood TC, Aslam T, Harmatz PR. Sohn YB, et al. Among authors: broqua p. Mol Genet Metab Rep. 2023 Dec 28;38:101041. doi: 10.1016/j.ymgmr.2023.101041. eCollection 2024 Mar. Mol Genet Metab Rep. 2023. PMID: 38234862 Free PMC article.
Author Correction: CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas.
Niborski LL, Gueguen P, Ye M, Thiolat A, Ramos RN, Caudana P, Denizeau J, Colombeau L, Rodriguez R, Goudot C, Luccarini JM, Soudé A, Bournique B, Broqua P, Pace L, Baulande S, Sedlik C, Quivy JP, Almouzni G, Cohen JL, Zueva E, Waterfall JJ, Amigorena S, Piaggio E. Niborski LL, et al. Among authors: broqua p. Nat Commun. 2023 May 30;14(1):3127. doi: 10.1038/s41467-023-38931-6. Nat Commun. 2023. PMID: 37253849 Free PMC article. No abstract available.
CD8+T cell responsiveness to anti-PD-1 is epigenetically regulated by Suv39h1 in melanomas.
Niborski LL, Gueguen P, Ye M, Thiolat A, Ramos RN, Caudana P, Denizeau J, Colombeau L, Rodriguez R, Goudot C, Luccarini JM, Soudé A, Bournique B, Broqua P, Pace L, Baulande S, Sedlik C, Quivy JP, Almouzni G, Cohen JL, Zueva E, Waterfall JJ, Amigorena S, Piaggio E. Niborski LL, et al. Among authors: broqua p. Nat Commun. 2022 Jun 29;13(1):3739. doi: 10.1038/s41467-022-31504-z. Nat Commun. 2022. PMID: 35768432 Free PMC article.
A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, Loomba R, Harrison SA, Balabanska R, Mateva L, Lanthier N, Alkhouri N, Moreno C, Schattenberg JM, Stefanova-Petrova D, Vonghia L, Rouzier R, Guillaume M, Hodge A, Romero-Gómez M, Huot-Marchand P, Baudin M, Richard MP, Abitbol JL, Broqua P, Junien JL, Abdelmalek MF; NATIVE Study Group. Francque SM, et al. Among authors: broqua p. N Engl J Med. 2021 Oct 21;385(17):1547-1558. doi: 10.1056/NEJMoa2036205. N Engl J Med. 2021. PMID: 34670042 Clinical Trial.
The pan-PPAR agonist lanifibranor reduces development of lung fibrosis and attenuates cardiorespiratory manifestations in a transgenic mouse model of systemic sclerosis.
Derrett-Smith E, Clark KEN, Shiwen X, Abraham DJ, Hoyles RK, Lacombe O, Broqua P, Junien JL, Konstantinova I, Ong VH, Denton CP. Derrett-Smith E, et al. Among authors: broqua p. Arthritis Res Ther. 2021 Sep 6;23(1):234. doi: 10.1186/s13075-021-02592-x. Arthritis Res Ther. 2021. PMID: 34488870 Free PMC article.
Pan-PPAR agonist lanifibranor improves portal hypertension and hepatic fibrosis in experimental advanced chronic liver disease.
Boyer-Diaz Z, Aristu-Zabalza P, Andrés-Rozas M, Robert C, Ortega-Ribera M, Fernández-Iglesias A, Broqua P, Junien JL, Wettstein G, Bosch J, Gracia-Sancho J. Boyer-Diaz Z, et al. Among authors: broqua p. J Hepatol. 2021 May;74(5):1188-1199. doi: 10.1016/j.jhep.2020.11.045. Epub 2020 Dec 2. J Hepatol. 2021. PMID: 33278455 Free article.
Discovery of novel quinoline sulphonamide derivatives as potent, selective and orally active RORγ inverse agonists.
Amaudrut J, Argiriadi MA, Barth M, Breinlinger EC, Bressac D, Broqua P, Calderwood DJ, Chatar M, Cusack KP, Gauld SB, Jacquet S, Kamath RV, Kort ME, Lepais V, Luccarini JM, Masson P, Montalbetti C, Mounier L, Potin D, Poupardin O, Rouaud S, Spitzer L, Wallace CD. Amaudrut J, et al. Among authors: broqua p. Bioorg Med Chem Lett. 2019 Jul 15;29(14):1799-1806. doi: 10.1016/j.bmcl.2019.05.015. Epub 2019 May 9. Bioorg Med Chem Lett. 2019. PMID: 31101472
Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR) α/γ/δ Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.
Boubia B, Poupardin O, Barth M, Binet J, Peralba P, Mounier L, Jacquier E, Gauthier E, Lepais V, Chatar M, Ferry S, Thourigny A, Guillier F, Llacer J, Amaudrut J, Dodey P, Lacombe O, Masson P, Montalbetti C, Wettstein G, Luccarini JM, Legendre C, Junien JL, Broqua P. Boubia B, et al. Among authors: broqua p. J Med Chem. 2018 Mar 22;61(6):2246-2265. doi: 10.1021/acs.jmedchem.7b01285. Epub 2018 Feb 27. J Med Chem. 2018. PMID: 29446942
36 results